Phenylmethimazole Decreases Toll-Like Receptor 3 and Noncanonical Wnt5a Expression in Pancreatic Cancer and Melanoma Together with Tumor Cell Growth and Migration

Anthony L. Schwartz,5 Ramiro Malgor,2 Eric Dickerson,1 Ashani T. Weeraratna,6 Andrzej Slominski,7 Jacobo Wortsman,8 Norikazu Harii,1 Aimee D. Kohn,9 Randall T. Moon,10 Frank L. Schwartz,3 Douglas J. Goetz,4,5 Leonard D. Kohn,1 and Kelly D. McCall3,5

Abstract

Purpose: To evaluate whether (a) Wnt5a expression in pancreatic cancer and malignant melanoma cells might be associated with constitutive levels of Toll-like receptor 3 (TLR3) and/or TLR3 signaling; (b) phenylmethimazole (C10), a novel TLR signaling inhibitor, could decrease constitutive Wnt5a and TLR3 levels together with cell growth and migration; and (c) the efficacy of C10 as a potential inhibitor of pancreatic cancer and malignant melanoma cell growth in vivo.

Experimental Design: We used a variety of molecular biology techniques including but not limited to PCR, Western blotting, and ELISA to evaluate the presence of constitutively activated TLR3/Wnt5a expression and signaling. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide-based technology and scratch assays were used to evaluate inhibition of cell growth and migration, respectively. TLR3 regulation of cell growth was confirmed using small interfering RNA technology. Nude and severe combined immunodeficient mice were implanted with human pancreatic cancer and/or melanoma cells and the effects of C10 on tumor growth were evaluated.

Results: We show that constitutive TLR3 expression is associated with constitutive Wnt5a in human pancreatic cancer and malignant melanoma cell lines, that C10 can decrease constitutive TLR3/Wnt5a expression and signaling, suggesting that they are interrelated signal systems, and that C10 inhibits growth and migration in both of these cancer cell lines. We also report that C10 is effective at inhibiting human pancreatic cancer and malignant melanoma tumor growth in vivo in nude or severe combined immunodeficient mice and associate this with inhibition of signal transducers and activators of transcription 3 activation.

Conclusions: C10 may have potential therapeutic applicability in pancreatic cancer and malignant melanoma.

Pancreatic cancer and malignant melanoma are difficult to treat and have poor prognoses. The American Cancer Society estimates that 37,680 people will have been diagnosed with pancreatic cancer in 2008, with an expected death rate of 92%. It is the fourth leading cause of cancer deaths in the United States and has an overall survival rate of <4%; most die within 6 months to 1 year from time of diagnosis. Malignant melanoma exceeds many other types of cancers in lost "years of life" because it is most prevalent in younger individuals. The poor prognosis is attributable to a highly invasive nature, metastases before discovery, and a poor response to chemotherapeutic and/or surgical intervention. Uncovering a potentially effective treatment for both carcinoma of the pancreas and malignant melanoma is therefore of importance, particularly if the therapy has a novel molecular basis and is applicable to both.

The Wingless (Wnt) family of secreted glycoproteins control early developmental processes including cellular migration, differentiation, and proliferation (reviewed in ref. 1). "Canonical" Wnts modulate cell growth by increasing β-catenin levels, β-catenin nuclear localization, and binding to the LEF/TCF
family of transcription factors, which can trigger the expression of genes controlling cell growth (2–4). Noncanonical (β-catenin-independent) Wnt signaling is thought to modulate cell proliferation by inducing the release of intracellular Ca^{2+} and activating both protein kinase C (5) and calcium-calmodulin kinase II. Noncanonical Wnt5a is up-regulated in many types of human cancers, including malignant melanoma and pancreatic cancer (6–9). The role of Wnt5a in oncogenesis is, however, not fully understood. On the one hand, Wnt5a is categorized as a nontransforming Wnt in studies in the C57MG mouse mammary epithelial cell (10–12); on the other hand, a recent study suggests that Wnt5a activation of protein kinase C contributes to enhanced motility and invasiveness of malignant melanoma cells (7).

Recently, we showed that high constitutive Wnt5a might be linked to high constitutive TLR3 signaling and that the TLR3/ Wnt5a association might be important in cancer cell growth and migration (13). TLRs on immune cells are the basis of our multigenic, innate immune, inflammatory response to signature molecules of environmental pathogens that cause tissue damage; they signal an important host defense mechanism (14). Inappropriate TLR expression in nonimmune cells, might be useful to inhibit the growth and migration of PTC and (d) C10 significantly inhibits the growth of human pancreatic cancer and melanoma tumor cells in vitro; and (d) C10 significantly inhibits the growth of pancreatic cancer and malignant melanoma in vivo in nude and severe combined immunodeficient mouse models in association with inhibition of signal transducers and activators of transcription 3 activation. Inhibitors of abnormally expressed, TLR3-induced, innate immune signaling in nonimmune cells, by agents such as C10, may be useful therapeutics in pancreatic cancer and malignant melanoma.

Translational Relevance
Pancreatic cancer and malignant melanoma have poor prognoses because of their highly invasive nature, metastases before discovery, and limited response to chemotherapeutic or immunotherapeutic intervention. This report describes a novel therapeutic approach applicable to both pancreatic cancer and malignant melanoma. We show that (a) Toll-like receptor 3 (TLR3), like Wnt5a, is constitutively expressed in human pancreatic cancer and malignant melanoma cells; (b) phenylmethimazole (C10), an inhibitor of TLR3 signaling, can decrease constitutive TLR3 and Wnt5a expression and signaling, suggesting that they are interrelated signal systems; (c) C10 significantly inhibits the growth of human pancreatic cancer and melanoma tumor cells in vitro; and (d) C10 significantly inhibits the growth of pancreatic cancer and malignant melanoma in vivo in nude and severe combined immunodeficient mouse models in association with inhibition of signal transducers and activators of transcription 3 activation. Inhibitors of abnormally expressed, TLR3-induced, innate immune signaling in nonimmune cells, by agents such as C10, may be useful therapeutics in pancreatic cancer and malignant melanoma.

Materials and Methods
Materials. Anti-phospho-STAT3^{Ser727}, recombinant IL-6, and the IL-6 ELISA were from Biosource International. Anti-phospho-STAT3^{Ser705} and anti-β-actin were from Cell Signaling. Polyinosinic-cytidylic acid [poly(I:C); a synthetic dsRNA], psiRNA-hTLR3, psiRNA-hTLR4, and psiRNA-scrambled were from InvivoGen. C10 was a gift of Interthyr (poly(I:C); a synthetic dsRNA), psiRNA-scrambled were from InvivoGen. C10 was a gift of Interthyr and was prepared as 200 mmol/L stock solution in DMSO (Sigma-Aldrich). The source of all other materials was the same as reported previously or is noted below (13, 16).

Cells. The melanoma cell lines UACC647, UACC1273EV, and M93-047 have been described (10). All melanoma and BXPC-3 cells were grown in RPMI 1640 supplemented with 2 g/L sodium bicarbonate, 1.4 mmol/L sodium pyruvate, 0.14 mmol/L nonessential amino acids, and 10% fetal bovine serum (pH 7.2). PANC-1 and BXPC-3 cells were
generously provided by Dr. Duxin Sun (The Ohio State University). PANC-1 and HEK 293 cells were grown in DMEM supplemented with 10% fetal bovine serum. WRO 82-1 and ARO 81-1 cells provided by Dr. Guy Juillard (University of California at Los Angeles) were maintained as described previously (13).

PANC-1 cell lines stably overexpressing small interfering RNA (siRNA) against human TLR3, TLR4, or a scrambled control sequence (negative) were made by transfection with either psiRNA-hTLR3, psiRNA-hTLR4, or psiRNA-scrambled using Lipofectamine 2000 reagent (Invitrogen). Two days post-transfection, zeocin (100 µg/ml) was added to select for plasmid-containing cells, and stable transfectants were isolated following 2 weeks in zeocin (100 µg/ml). Clones were analyzed for siRNA expression using standard real-time PCR (RT-PCR) methods. The rate of cell proliferation was measured using the Bromodeoxyuridine Cell Proliferation Assay Kit (Chemicon International).

**RT-PCR.** Total RNA was isolated using the RNeasy Mini Kit (Qiagen) according to the manufacturer's instructions. DNA was removed from total RNA during total RNA isolation using the RNeasy-Free DNase set (Qiagen). Human TLR3, Wnt5a, CXCL10, IFN-β, and IL-6 expression levels were measured by qRT-PCR with gene-specific primers designed using the Plexor primer design software (Promega) and the Plexor One-Step qRT-PCR System (Promega) according to the manufacturer's instructions. For accuracy, human glyceraldehyde-3-phosphate dehydrogenase was co-amplified with TLR3, Wnt5a, CXCL10, IFN-β, and IL-6 each in separate multiplex reactions. Human glyceraldehyde-3-phosphate dehydrogenase primers were obtained from Biosearch Technologies. The ΔCt method of RT-PCR analysis was used for comparison of values.

Total RNA was isolated using the RNeasy Mini Kit (Qiagen) according to the manufacturer's instructions. DNA was removed from total RNA using the DNA-Free kit (Ambion) according to the manufacturer's instructions. A total of 1 µg RNA was then used to synthesize cDNA using the Advantage RT-for-PCR Kit (BD Biosciences) according to the manufacturer's protocol. A total of 50 ng cDNA was subsequently used for PCR of TLR-3, β-actin, and Wnt5a, and 250 ng cDNA was used for IFN-β and CXCL10. These primers and reaction conditions used have been described previously (13).

**Luciferase assays and plasmids.** Plasmids were constructed and luciferase assays were done as described (13, 16).

**Western blot analysis.** Nuclear proteins were isolated using the NE-PER Nuclear and Cytoplasmic Isolation kit (Pierce) according to the manufacturer's instructions. Protein (30 µg) was resolved on denaturing gels using the Nu-PAGE System (Invitrogen) unless otherwise noted. All proteins were transferred to nitrocellulose membranes and subsequent antibody binding was revealed using Enhanced Chemiluminescence Plus reagents (Amersham Pharmacia Biotech).

**ELISA analysis.** Cells were treated with either 0.5 mmol/L C10 or equal amounts of DMSO for 24 h. Cell supernatants were collected and IL-6 levels were determined using a human IL-6 ELISA (control solvent), another with 1 and/or 3mg/kg C10, and a final group either “mock” injected (received only mechanical puncturing intra-peritoneally via the syringe) or untreated. The pancreatic cancer experiment was carried out for 50 days in total, whereas the melanoma experiments were carried out for 2 weeks.

Statistics. All experiments were replicated at least three times on different groups of cells. All data are expressed as mean ± SD. Data in Figs. 1C, 2 to 4, and 6B and C were evaluated for statistical significance using one-way ANOVA, and statistical significance for comparison of means of different groups was calculated using the Tukey-Kramer multiple comparison post hoc analysis using NCSS software. The differences were considered significant at P values indicated in the figure legends.

**Results**

**TLR3 and Wnt5a RNA levels are constitutively expressed in human pancreatic cancer and melanoma cell lines.** Wnt5a is expressed in a variety of human cancers (6–9). We analyzed expression of TLR3 and Wnt5a RNA in two human pancreatic cancer and five different human melanoma cell lines (Fig. 1A). RT-PCR revealed the expression of TLR3 and Wnt5a in 100% of the cell lines analyzed (Fig. 1A). RT-PCR was confirmed by real-time PCR (data not shown). That these were high constitutive TLR3 and Wnt5a levels was confirmed by studies with C10, which decreased these levels significantly in all cases (see below), and by comparison with two purported thyroid cancer cell lines, which do not express TLR3 or Wnt5a (Fig. 1A; ref. 13).

**Scratch assays.** Scratch assays were done as described (7). Briefly, confluent cells were scratched using a sterile pipette tip, treated or not with C10, and analyzed by digital photography for ability to heal the scratch.

**Statistics.** Luciferase assays were done as described (7). Briefly, confluent cells were scratched using a sterile pipette tip, treated or not with C10, and analyzed by digital photography for ability to heal the scratch.that C10 decreased the levels of IFN-β and CXCL10 together with TLR3 and Wnt5a support this suggestion (see below).

To further explore function, we questioned whether extracellular poly(I:C), which mimics the dsRNA ligand that binds to TLR3 (24, 30–34), could activate both the NF-κB and the IRF-3/IFN-β pathways in PANC-1 and M93-047 cells as in thyocytes and immune cells (13, 16, 24, 30–34). When poly(I:C) was incubated with RNA-cell-transfected cells and IFN-β-luciferase-transfected cells (Fig. 1C), it caused a statistically significant increase in NF-κB-luciferase activity by comparison with nontreated cells (Fig. 1C) or cells transfected with control plasmid alone (data not shown). Poly(I:C) incubation more significantly increased IFN-β promoter activity in PANC-1 cells by comparison with nontreated cells (Fig. 1C) or cells transfected with control plasmid alone (data not shown). Similar results were seen in another pancreatic cell line (BXPC3; data not shown); however, transfection difficulties prevented similar studies being completed in the human melanoma cell lines. The data in Figs. 1 and 2, which showed high
constitutive levels of IFN-β and CXCL10 as well as TLR3, was, nevertheless, an indication of potential TLR3 functionality in the melanoma cell lines.

Phenylmethimazole (C10) can inhibit dsRNA signaling by its ability to inhibit the TLR3-mediated IRF-3/IFN-β pathway and can inhibit STAT activation in FRTL-5 thyrocytes (16). FRTL-5 thyrocytes do not express Wnt5a (29), suggesting that the primary action of C10 is on TLR signaling. We took advantage of this C10 activity to explore the functional role of TLR3 in pancreatic cancer and malignant melanoma cells as well as the relationship between TLR3 and Wnt5a.

C10 inhibits TLR3 expression and signaling in human cancer cells. Using (a) poly(I:C)-induced NF-κB activation in PANC-1 cells transfected with the NF-κB-luciferase construct or (b) poly(I:C)-induced promoter activity in IFN-β-luciferase-transfected PANC-1 cells, we could show C10 significantly inhibited both by comparison with control solvent (DMSO)-treated cells (Fig. 1C).

Our previous studies showed that C10 decreased high constitutive TLR3 in the purported PTC cells and high levels of TLR3 induced by dsRNA transfection of normal thyrocytes (13, 16). We thus evaluated the effect of C10 on the high constitutive levels of TLR3 RNA in the human pancreatic cancer cell line PANC-1 and the human melanoma cell line M93-047. As was the case in PTC cells, we observed significant decreases in TLR3 RNA levels following C10 treatment in PANC-1 and M93-047 cells (Fig. 2A).

Also in agreement with our previous observations (13), C10 significantly decreased expression of Wnt5a RNA levels in PANC-1 and M93-047 cell lines (Fig. 2B), again exposing a potential functional relationship between the high constitutive Wnt5a and TLR3.

C10 treatment of PANC-1 and M93-047 cells also significantly decreased the products (24, 35–37) of the TLR3 signal, IFN-β and CXCL10 (Fig. 2C). In PANC-1 cells, CXCL10 expression was statistically different when comparing the solvent (DMSO)
control and C10 treatment groups despite that no “statistical” difference was found between the untreated control group and the C10 treatment group (Fig. 2C). IL-6 is another TLR3-signaling product important for the growth and migration of cancer cells (24, 38, 39). Constitutive expression of IL-6 was significantly reduced by C10 in PANC-1 and M93-047 cells as determined by both real-time PCR (Fig. 2D) and ELISA (Fig. 2D) analyses. C10 affect on constitutive IL-6 expression was dose-dependent; inhibition relative to control was 17.7% at 0.125 mmol/L and 62.7% at 0.50 mmol/L. In M93-047 cells, solvent (DMSO) treatment also decreased constitutive IL-6 protein levels compared with untreated cells; however, compared with DMSO, C10 significantly further reduced constitutive IL-6 levels. This phenomenon was not seen in PANC-1 cells (Fig. 2D).

The data in Figs. 1 and 2 support the conclusion that the constitutive levels of TLR3 are abnormally high in the pancreatic carcinoma and malignant melanoma cells as evident in the index cells, PANC-1 and M93-047 melanoma cells. In addition, as is the case in the purported PTC cells, TLR3 expression levels and TLR3 signaling can be effectively lowered by C10.

C10 inhibits pancreatic cancer and melanoma growth and migration and down-regulates potential downstream signals of growth modulated by TLR3. In addition to its effect on constitutive TLR3 and Wnt5a RNA levels and function, 0.5 mmol/L C10 treatment of PANC-1 and M93-047 cells led to significant inhibition of cell growth (Fig. 3A). Furthermore, treatment of PANC-1 and M93-047 cells with 0.5 mmol/L C10 led to significant inhibition of motility/migration as measured using scratch assays (Fig. 3B). In a scratch assay, migration to cover a scratched area on the plate surface is measured; retention of a visible scratch line as in Fig. 3B (+C10) is evidence of inhibition of cell migration (7). Effects in both assays were evident with 0.1 and 0.25 mmol/L C10 treatment and maximal at 0.5 mmol/L (data not shown); thus the 0.5 mmol/L concentration was used in all previous and following in vitro experiments.

To ensure that TLR3 was driving cell growth, we transfected cells with TLR3 siRNA. Compared with the control “scrambled” siRNA PANC-1 cell line and normal PANC-1 cell line, PANC-1 cells expressing the TLR3 siRNA grew significantly slower than control cells as measured by bromodeoxyuridine incorporation (Fig. 4). Interestingly, PANC-1 cells expressing the TLR4 siRNA also grew significantly slower than “scrambled” siRNA PANC-1 cells; however, they did not grow significantly slower than normal PANC-1 cells (Fig. 4). In addition, PANC-1 cells expressing the TLR3 siRNA grew significantly slower than the PANC-1 cells expressing TLR4 siRNA (Fig. 4), suggesting that TLR3 signaling is more important for proliferation of PANC-1 cells than TLR4 signaling. Compared with control cells transfected with scrambled siRNA, TLR3 siRNA and TLR4 siRNA inhibited STAT3 phosphorylation together with, and apparently proportional to, their effects on growth (data not shown).

Fig. 2. C10 decreases constitutive TLR3, Wnt5a, CXCL10, IFN-β, and IL-6 RNA as well as IL-6 protein levels in human pancreatic cancer and melanoma cells. PANC-1 and M93-047 cells were treated with 0.25% DMSO or 0.5 mmol/L C10 for 24 h. RT-PCR was done to evaluate TLR3, Wnt5a, CXCL10, IFN-β, and IL-6 RNA levels (A-D) and IL-6-specific ELISA was done to evaluate IL-6 protein levels (D). *, P < 0.05; +, P < 0.00000001, significant differences between groups.
Activated STAT3 is known to mediate uncontrolled cell growth in many types of human cancers, and IL-6, a proinflammatory cytokine produced as a result of active TLR signaling, is known to activate STAT3 (reviewed in ref. 28). STAT3 is phosphorylated on multiple residues for activation; phosphorylation of both its Tyr705 and Ser727 residues are necessary for maximal transcriptional activity (40–43). Based on our findings that C10 significantly reduces TLR3 gene expression and TLR3 signaling and with the knowledge that IL-6 is a product of the TLR signaling pathway, we asked if C10 inhibited PANC-1 and M93-047 constitutive STAT3 and IL-6-induced activation.

Constitutive STAT3 phosphorylation was detected in both cell lines. We observed large decreases in phospho-STAT3 Tyr705 in PANC-1 and STAT3 Ser727 in M93-047 cells with 0.5 mmol/L C10 treatment (Fig. 5); likewise, C10 treatment produced a large decrease in IL-6-induced phospho-STAT3 Tyr705 protein levels in PANC-1 cells and in phospho-STAT3 (S727) protein levels in M93-047 cells (Fig. 5). C10 inhibition of IL-6-induced phospho-STAT3 protein levels was dose dependent (data not shown).

Interestingly, C10 did not affect STAT3 Ser727 phosphorylation in PANC-1 or STAT3 Tyr705 in M93-047 cell lines reflecting individual variations of STAT3 phosphorylation among different cancers. Phosphorylation of STAT3 at Ser727 and Tyr705 is mediated by a variety of kinase signaling pathways in response to various stimuli. STATs are known to be phosphorylated at Tyr705 by JAKs and at Ser727 by members of the mitogen-activated protein kinase and JNK family of serine kinases. Rho GTPases (RhoA, Cdc42, and Rac1) can efficiently modulate STAT3 transcriptional activity by inducing the simultaneous phosphorylation of Tyr705 and Ser727. It is unclear at this time why C10 differentially regulates STAT3 phosphorylation of tyrosine and serine residues in PANC-1 and M93-047 cells. Of note, separate studies conducted in cells purported to be PTC cells, but now recognized to be melanoma and colon cancer cells, revealed significant inhibition of STAT3 phosphorylation at both Ser727 and Tyr705, which correlated with inhibition of cell growth and migration (13). Preliminary studies, revealed no effects of C10 on AKT and mitogen-activated protein kinase activation (data not shown). Additional studies are in progress to investigate the mechanism of this differential regulation of STAT3 phosphorylation by C10 in these tumor cell lines.

Despite C10 inhibition of phosphorylation on different sites on the STAT3 molecule, inhibition of either should result in similar down-regulation of STAT3 transcriptional activity as noted in the literature (40–43). Of note, despite the significant reduction in constitutive IL-6 protein levels by DMSO in M93-047 cells (Fig. 2D), DMSO had no effect on STAT3 phosphorylation, growth, or migration of these cells (Figs. 3 and 5).
DMSO has been reported to affect protein turnover (44); this was not evaluated here.

**C10 inhibits tumor growth and STAT3 phosphorylation in vivo.** As an initial validation of the relevance of the ability of C10 to inhibit cancer cell growth in vivo in tumors, which pathologically express TLR3 and downstream signaling, we evaluated the effect of C10 on human pancreatic and melanoma tumor growth in multiple mouse models. Both PANC-1 and M93-047 cells were injected subcutaneously with C10, at doses shown to be effective when given prenterally in other animal models wherein TLR signaling is important for disease expression (colitis, toxic shock, etc.; refs. 45, 46). As can be seen, C10 was able to considerably inhibit the number of tumors in human pancreatic implants as only 3 of 12 animals even exhibited tumors (Fig. 6A). Consistent with the effects of C10 in PANC-1 cells in vitro, it also significantly reduced phospho-STAT3Tyr705 levels in the pancreatic tumors in these mice (Fig. 6A). In the melanoma models (Fig. 6B and C), tumor number was not decreased; however, the size of the tumors was significantly decreased. C10 had no effect on coat texture or food intake, nor did it cause systemic toxicity (Fig. 6C, a). Given daily for as long as 3 months, there has been no evidence of thyroid function changes, changes in TSH levels, and liver or kidney toxicity with C10 treatment.

**Discussion**

In previous work in which we studied cells purported to be papillary thyroid carcinomas (but now known to be melanoma cells), we showed that high constitutive levels of TLR3 and Wnt5a are coordinately expressed and regulated, functional and linked to cell growth and migration (13). We also found that phenylmethimazole (C10), which decreases TLR3 levels and signaling in FRTL-5 thyrocytes [cells that do not express Wnt5a (16, 29)], reduces Wnt5a as well. This report offers several novel observations based on the hypothesis that this might not be a unique phenomenon but typical of many tumor cells reported to have high Wnt5a levels in vivo and in vitro. First, we show that pancreatic cancer and melanoma cells derived from human tumors also coordinately express high constitutive levels of functional TLR3 and Wnt5a. Second, we show for the first time that the high constitutive levels of both TLR3 and Wnt5a in human pancreatic cancer and melanoma cells are returned toward normal levels by treatment with C10, which acts on TLR3 signaling in the presence or absence of Wnt5a (13, 16, 29). Third, C10 decreased Wnt5a and TLR3 levels are associated with decreased STAT3 activation as well as pancreatic cancer and melanoma cell growth and motility in vitro. Last, C10 inhibits tumor growth in vivo in a mouse model of human pancreatic cancer and mouse models of malignant melanoma.

A role for TLR3 in cancer progression has been described and has been shown to signal via intermediates such as protein kinase C and STAT3 in multiple cell types (13, 47). The relationship between IL-6, STAT3 activation, protein kinase C, and Wnt5a levels appears to be more cell specific. In cardiac myocytes and thyrocytes, IL-6-activated STAT3 can increase Wnt5a (13, 48). In contrast, IL-6 increases in melanoma cells have smaller effects on STAT3 activation, due to high levels of SOCS3 expression, yet Wnt5a requires STAT3 to affect its downstream signal transduction (49). Both protein kinase C and STAT3 have been shown to increase, and be increased by, Wnt5a (13, 48, 49). Our previous work in the purported PTC cells (13) led us to generate a speculative model in which an inciting event can cause carcinoma cells to increase TLR3. TLR3 signal generation via TRIF/TICAM-1/IRF-3 increases IFN-β, which can act as an autocrine/paracrine factor to further increase TLR3 (16). TLR3 induction of both NF-κB and IFN-β signal pathways contribute to increases in IL-6 (31, 50) and the subsequent activation of STAT3, which then increases Wnt5a. C10 inhibits the TLR3-activated IRF-3 signaling, IRF-3-dependent increase in IFN-β, and TLR3-induced increase in STAT3 phosphorylation. Phospho-STAT3 appears critical to both the increase in Wnt5a and the growth and motility of the cells; cytokines and chemokines resultant from overexpressed TLR3 signaling are important in this process. The data presented herein support this speculative model and
hypotheses, suggesting that TLR3 and consequently Wnt5a signaling are important mediators of cell growth and migration in a subset of human cancers.

It has long been recognized that Wnt5a is overexpressed in many types of human cancers including, but not limited to, malignant melanoma, breast, and prostate cancer (6–8); however, its role in these cancers is not yet known. Interestingly, the progression of these cancers is thought to be controlled by the activation of STAT3 (7, 13, 28, 49). We show here that C10 is able to inhibit (a) constitutive TLR3 expression and signaling, (b) activation of STAT3, (c) growth and migration of human pancreatic cancer and melanoma cells in culture, and (d) pancreatic cancer and human melanoma tumor growth in mouse models. Taken together, these data are highly suggestive that TLR3 signaling is important for regulating cell growth, Wnt5a expression, and cell motility in a variety of human cancers and that TLR3 and Wnt5a signaling systems are interrelated. These data open new doorways for studies of cancers, which appear to involve TLR3/Wnt5a signaling, and raise the possibility that C10 may have potential efficacy as an anticancer agent in tumors, which express high constitutive levels of TLR3 and Wnt5a.

**Disclosure of Potential Conflicts of Interest**

A.L. Schwartz, D.J. Goetz, L.D. Kohn, F.L. Schwartz, and K.D. McCall are participants of a pending STTR research grant submitted by the Interthyr Corporation. They and R. Malgor are co-inventors on a patent for C10. A.L. Schwartz, D.J. Goetz and K.D. McCall have previously consulted for the Interthyr Corporation. L.D. Kohn is the President of the Interthyr Corporation. D.J. Goetz is a shareholder and on the Board of Directors of the Interthyr Corporation. E. Dickerson was previously employed by the Interthyr Corporation. R.T. Moon has financial interest in and is a consultant for Fate Therapeutics, Inc., La Jolla, CA.

---

**Fig. 6.** C10 inhibits tumor growth in a nude mouse model of pancreatic cancer and in nude and SCID mouse models of human melanoma. Each mouse in the pancreatic cancer nude mouse model was injected with 500,000 PANC-1 cells, and each nude and SCID mouse in the melanoma experiments received $1 \times 10^6$ melanoma cells. Cells were subcutaneously placed behind the neck. Mice were then either left untreated or treated with 10% DMSO, C10, or “mock” injected for 50 days in the pancreatic cancer experiment or 2 weeks in the melanoma experiments. “Mock” injection = insertion of a comparable syringe needle. (A) C10 largely prevented tumor formation and decreased phospho-STAT3Tyr705 levels in C10-treated animals. Bands from Western analysis were quantitated using ImageGauge 3.12 software and data are represented as relative gene expression levels, which were standardized against the internal control gene $\beta$-actin ($n = 12$ mice per group). (B) nude mice were injected with human melanoma cells as described above and treated. Data are represented as average tumor weight, and representative tumors from each group are also depicted. (C) SCID mice injected with human melanoma cells at 2 weeks post-injection. No abnormal changes in coat texture and/or appearance was observed in any mice as particularly illustrated by the mouse in a, which has a large control tumor yet was active and not cachectic. Mice displayed in b, d, and f have coats saturated with alcohol before tumor excision to allow better visualization of tumors. c, e, and g, tumors excised from mice in b, d, and f, respectively. (h) average tumor mass per group of SCID mice. Bars, SD. *, $P < 0.05$; +, $P < 0.01$, significant differences between untreated and C10-treated groups.
References


4122 www.aacrjournals.org

Downloaded from clinicanccereres.aacrjournals.org on April 20, 2017. © 2009 American Association for Cancer Research.
Clinical Cancer Research

Phenylmethimazole Decreases Toll-Like Receptor 3 and Noncanonical Wnt5a Expression in Pancreatic Cancer and Melanoma Together with Tumor Cell Growth and Migration

Anthony L. Schwartz, Ramiro Malgor, Eric Dickerson, et al.


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/15/12/4114

Cited articles
This article cites 48 articles, 19 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/15/12/4114.full.html#ref-list-1

Citing articles
This article has been cited by 2 HighWire-hosted articles. Access the articles at:
/content/15/12/4114.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.